Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Average Recommendation of “Moderate Buy” by Brokerages

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) has been given a consensus recommendation of “Moderate Buy” by the five research firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $8.3333.

Several brokerages have recently issued reports on AUTL. William Blair reiterated an “outperform” rating on shares of Autolus Therapeutics in a research note on Wednesday, September 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Autolus Therapeutics in a research note on Wednesday, October 8th. Needham & Company LLC reiterated a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a report on Monday, November 3rd. Wells Fargo & Company dropped their price objective on shares of Autolus Therapeutics from $6.00 to $5.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 13th. Finally, Wall Street Zen cut shares of Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 15th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Knott David M Jr purchased a new stake in Autolus Therapeutics during the first quarter worth approximately $651,000. Atle Fund Management AB increased its stake in Autolus Therapeutics by 130.5% in the second quarter. Atle Fund Management AB now owns 1,105,461 shares of the company’s stock valued at $2,520,000 after purchasing an additional 625,817 shares during the last quarter. Armistice Capital LLC raised its holdings in Autolus Therapeutics by 19.6% during the first quarter. Armistice Capital LLC now owns 11,000,000 shares of the company’s stock worth $17,050,000 after purchasing an additional 1,800,000 shares in the last quarter. Cetera Investment Advisers lifted its position in shares of Autolus Therapeutics by 47.3% during the 1st quarter. Cetera Investment Advisers now owns 524,872 shares of the company’s stock worth $814,000 after buying an additional 168,650 shares during the last quarter. Finally, Vident Advisory LLC acquired a new position in shares of Autolus Therapeutics in the 1st quarter valued at $241,000. 72.83% of the stock is owned by institutional investors and hedge funds.

Autolus Therapeutics Price Performance

NASDAQ:AUTL opened at $1.23 on Monday. The company has a fifty day simple moving average of $1.49 and a two-hundred day simple moving average of $1.81. The company has a market cap of $327.35 million, a price-to-earnings ratio of -1.48 and a beta of 1.84. Autolus Therapeutics has a 52 week low of $1.11 and a 52 week high of $3.45.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.07). Autolus Therapeutics had a negative net margin of 439.69% and a negative return on equity of 63.76%. The company had revenue of $21.14 million during the quarter, compared to analyst estimates of $21.08 million. On average, analysts expect that Autolus Therapeutics will post -0.94 EPS for the current year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.